Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

How Bayer’s 1Q 2026 Results Beat Expectations, Despite Patent Cliffs and Litigation

Explore Bayer AG’s Q1 2026 results: Crop Science’s €3.1bn revenue surge, Pharma’s patent‑cliff strategy, and a €7bn legal settlement’s impact on earnings.

Lisa Martinez

13/05/2026, 21:20

5 minutes to read

Hengrui‑BMS Deal: $15 B Strategic Partnership Boosting China’s Biopharma Future

Jiangsu Hengrui‑BMS deal: a $15 billion pharma partnership unlocking early‑stage oncology assets, cash infusions, milestone payouts, and global market access for Chinese biopharma.

Lisa Martinez

13/05/2026, 02:13

5 minutes to read

Genmab’s Share Bounce: ADC Expansion, Investor Confidence, & M&A Outlook

Genmab’s Q1 results show growth, but expanding the petosemtamab trial risks investor confidence; analysts stay bullish, citing pipeline strength and M&A prospects.

Lisa Martinez

12/05/2026, 00:18

6 minutes to read

Johnson & Johnson Accelerates U.S. Innovation to Outpace Biopharma Competition

Johnson & Johnson highlights U.S. innovation as a key driver to boost drug development, market access, and M&A in the biopharma sector, tackling patent cliffs and competition.

Lisa Martinez

10/05/2026, 18:39

4 minutes to read

Fosun Secures $350‑$450M Drug Revenue Boost With New Approval

Fosun Pharmaceutical’s new drug approval promises $350‑450M sales in 3 years, boosting market access, securing 10‑year exclusivity, and opening M&A and partnership opportunities.

Lisa Martinez

10/05/2026, 08:23

3 minutes to read

Pharma & Biotech Strategies to Thrive Amid Hong Kong Market Turbulence

Explore how Hong Kong’s market downturn shapes pharma & biotech strategies—value‑based contracts, patent cliffs, digital health, and M&A tactics for long‑term growth.

Lisa Martinez

10/05/2026, 07:23

4 minutes to read

Pfizer’s 2024 Dividend Move: Market Impact, Oncology Growth, and Patent‑Cliff Strategies

Pfizer’s latest market analysis shows a stable dividend strategy amid competitive oncology dynamics, patent cliffs, and targeted M&A plans.

Lisa Martinez

09/05/2026, 21:28

4 minutes to read

Hang Seng Falls 1%: Pharma & Biotech Firms Face Patents, Payers, and M&A Push

Hong Kong’s Hang Seng Index fell 1% as drug‑dev firms WuXi AppTec and Hansoh Pharma slipped, yet market‑access tactics, biosimilar plans and strategic M&A offer pharma investors hope for resilience and long‑term growth.

Lisa Martinez

09/05/2026, 12:22

4 minutes to read

AbbVie’s May 8 Meeting: Growth, Immunology & Oncology Focus Boost Shareholder Value

AbbVie’s May 8 shareholder meeting revealed steady revenue growth, a cash‑flow‑rich outlook, and a focused immunology‑oncology expansion plan—highlighting next‑gen biologics, strategic M&A, and a disciplined ROI strategy for future pipeline success.

Lisa Martinez

08/05/2026, 19:16

4 minutes to read

AbbVie to Spotlight Strategic Growth, Pricing & M&A Plans at Bank of America Healthcare Conference – May 13, 2026

AbbVie’s Bank of America Healthcare Conference fireside chat reveals its strategy for tackling patent cliffs, expanding oncology, immunology, and neuroscience pipelines, and driving global growth.

Lisa Martinez

08/05/2026, 01:15

4 minutes to read

Newer articles Older articles